Welcome to AIDS PATIENT CARE AND STDS, a leading journal dedicated to the comprehensive exploration of clinical practices, research advancements, and public health strategies centered around HIV/AIDS and sexually transmitted diseases. Published by Mary Ann Liebert, Inc., this esteemed journal has been at the forefront of disseminating critical findings since 1996, contributing to a robust understanding of the complexities surrounding these global health issues. With an impressive impact factor reflected in its 2023 Q1 quartile rankings in both Infectious Diseases and Public Health, Environmental and Occupational Health, the journal stands out among its peers, ranking at the 95th percentile for Public Health and 91st percentile in Infectious Diseases. Researchers, healthcare professionals, and students will benefit from its rich content, comprehensive studies, and critical reviews that aim to improve care practices and health outcomes. With a clear commitment to fostering knowledge and collaboration in the field, AIDS PATIENT CARE AND STDS is an essential resource for those dedicated to combating these pressing health challenges.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

AIDS REVIEWS, published by Permanyer Publishing, is a distinguished academic journal dedicated to providing comprehensive insights into the field of AIDS research. Since its inception in 2000, the journal has served as a vital platform for disseminating knowledge on various aspects of HIV/AIDS, including prevention, treatment advancements, and socio-medical implications. With a commendable Q3 ranking in both Infectious Diseases and Medicine (miscellaneous), as well as Pharmacology (medical) in 2023, the journal has made significant strides in the academic community, covering relevant topics and emerging trends up to 2024. Although not open access, AIDS REVIEWS continues to attract contributions from leading researchers and professionals, fostering a collaborative environment aimed at improving health outcomes related to AIDS. Located in Barcelona, Spain, this journal is an essential resource for anyone dedicated to advancing their understanding of this global health challenge.

Sahara J-Journal of Social Aspects of HIV-AIDS, published by TAYLOR & FRANCIS LTD, is a distinguished open-access journal that has been contributing to the discourse surrounding HIV/AIDS since its inception in 2004. Operating from the United Kingdom, this journal aims to provide a comprehensive platform for researchers, professionals, and students to explore the social dimensions of HIV/AIDS, fostering an understanding of its impact on health, public policy, and societal norms. With an increasing impact factor and ranking within the Q3 category across various health-related fields, including Social Sciences, Infectious Diseases, and Public Health, Sahara J serves as a vital resource for interdisciplinary studies. Its commitment to open-access publishing ensures that vital research findings are freely available to a global audience, promoting widespread dissemination of knowledge and ultimately enhancing collaborative efforts to address the ongoing challenges posed by HIV/AIDS. As we navigate a rapidly evolving landscape in public health, this journal remains dedicated to advancing critical insights and fostering informed dialogues within the academic community.

Current HIV/AIDS Reports, published by Springer, is a distinguished scholarly journal that addresses critical developments in the field of HIV/AIDS research. As a leading publication within the Q1 quartiles for both Infectious Diseases and Virology, it serves as an essential platform for researchers and healthcare providers aiming to advance knowledge and practices related to HIV prevention, treatment, and care. With a commitment to publishing innovative studies, reviews, and clinical guidelines, this journal fosters a comprehensive understanding of the complexities surrounding HIV/AIDS. The journal enjoys a robust reputation, evidenced by its impressive Scopus rankings, including a rank of #69 in Infectious Diseases and #21 in Virology, placing it in the top echelons of its field. With an open-access model, *Current HIV/AIDS Reports* significantly enhances the accessibility of crucial research findings to a global audience, driving progress in HIV/AIDS knowledge and public health.

Current Opinion in HIV and AIDS is a pivotal journal published by Lippincott Williams & Wilkins, dedicated to the dissemination of cutting-edge research and insights in the rapidly evolving fields of HIV and AIDS. Established in 2007 and maintaining a comprehensive focus through to 2024, this journal has achieved an impressive position within academia, earning a Q1 ranking in multiple categories, including Hematology, Immunology, Infectious Diseases, Oncology, and Virology as of 2023, indicative of its high impact and relevance. Researchers and professionals benefit from its curated reviews that synthesize current knowledge, highlight emerging trends, and address clinical applications. While the journal is not open access, it remains a vital resource housed in prestigious databases, ensuring that vital information reaches a broad audience. The ISSN for print is 1746-630X and its E-ISSN is 1746-6318. Located in Philadelphia, PA, the journal's commitment to innovation and education makes it an essential platform for those engaged in combating one of the most pressing health challenges of our time.

JNCI Cancer Spectrum, published by Oxford University Press, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. With an impressive impact demonstrated through its Q1 ranking in both Cancer Research and Oncology categories for 2023, this journal provides a vital platform for disseminating high-quality research and innovative findings in a rapidly evolving landscape. Since its inception in 2017, JNCI Cancer Spectrum has embraced open access, enhancing the accessibility of evidence-based knowledge to researchers, professionals, and students across the globe. Additionally, it boasts notable positions in Scopus rankings, with a strong performance in both the Medicine and Biochemistry, Genetics and Molecular Biology categories. The journal is committed to its objectives of fostering collaborative efforts and encouraging dialogue among experts, making it an essential resource for anyone involved in cancer research.

AJAR - African Journal of AIDS Research, an esteemed publication by Taylor & Francis Ltd, stands at the forefront of research in the field of HIV/AIDS, with a specific focus on the African continent. Established in 2003 and publishing continuously through 2024, this journal serves as a crucial platform for disseminating innovative research findings aimed at addressing the challenges of HIV/AIDS. With its ISSN 1608-5906 and E-ISSN 1727-9445, AJAR is indexed in prominent databases and holds a respectable Q3 rating in major categories such as Infectious Diseases, Medicine, Public Health, and Virology as of 2023. This positions the journal as a relevant resource for scholars and medical professionals looking to stay informed on the latest developments and strategies in AIDS research. Although it is not currently an open-access journal, AJAR provides readers with valuable insights that are essential for advancing public health initiatives and infectious disease research across Africa and beyond. The journal's commitment to high-quality peer-reviewed research underscores its importance within its field, making it a vital resource for researchers, students, and policymakers alike.

JCO Global Oncology is a premier open-access journal published by Lippincott Williams & Wilkins, dedicated to the dissemination of high-quality research in the fields of cancer research and oncology. Since its inception in 2020, this journal has rapidly established itself as a vital resource for researchers, healthcare professionals, and students, holding a distinguished position in the Q2 category for both Cancer Research and Oncology based on the latest metrics. With an impressive Scopus rank of #61 out of 636 in General Medicine, the journal is recognized for its rigorous peer-reviewed articles and cutting-edge insights into oncological science. The open-access model ensures that vital research is readily available to a global audience, fostering collaborative advancements in the fight against cancer. JCO Global Oncology explores a broad range of topics and encourages submissions that contribute to the understanding, prevention, and treatment of various malignancies. With its substantial impact and ongoing contributions to the field, it stands as a promising platform for advancing oncological discourse and knowledge.

AIDS Research and Therapy is a prestigious peer-reviewed journal dedicated to disseminating cutting-edge research in the fields of AIDS and HIV therapy. Published by BMC, this Open Access journal has been freely available since its inception in 2004, facilitating global access to vital research findings. Based in the United Kingdom, the journal covers a diverse range of topics including molecular medicine, pharmacology, and virology, making it a crucial resource for researchers and clinicians alike. Recognized for its strong impact within the scientific community, it holds a Q2 quartile ranking in multiple categories as of 2023, including Molecular Medicine and Pharmacology. With an aim to enhance understanding and improve clinical outcomes for those affected by HIV/AIDS, AIDS Research and Therapy serves as an essential platform for the exchange of innovative ideas and practices that can inform future therapies and interventions. Researchers, professionals, and students seeking high-quality, peer-reviewed content will find this journal invaluable in advancing their knowledge and efforts in combating the HIV/AIDS epidemic.